M. M. Page

发表

Atypical case of alcohol-induced Cushingoid syndrome.

R. Jenkins, M. M. Page, 1981, British medical journal.

PCSK9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease

G. Watts, M. M. Page, 2018, Diabetes, obesity & metabolism.

Contemporary perspectives on the genetics and clinical use of lipoprotein(a) in preventive cardiology

G. Watts, M. M. Page, 2021, Current opinion in cardiology.

Clinical guidance on the contemporary use of proprotein convertase subtilisin/kexin type 9 monoclonal antibodies

G. Watts, N. Ward, M. M. Page, 2019, Diabetes, obesity & metabolism.

Coronary artery disease and the risk-associated LPA variants, rs3798220 and rs10455872, in patients with suspected familial hypercholesterolaemia.

G. Watts, J. Burnett, D. Chan, 2020, Clinica chimica acta; international journal of clinical chemistry.

Widening the spectrum of genetic testing in familial hypercholesterolaemia: Will it translate into better patient and population outcomes?

G. Watts, D. Bell, M. M. Page, 2019, Clinical genetics.

A variant in the fibronectin (FN1) gene, rs1250229-T, is associated with decreased risk of coronary artery disease in familial hypercholesterolaemia.

E. Moses, J. Burnett, D. Chan, 2022, Journal of clinical lipidology.

Lipoprotein apheresis and new therapies for severe familial hypercholesterolemia in adults and children.

G. Watts, J. Burnett, A. Hooper, 2014, Best practice & research. Clinical endocrinology & metabolism.

Ten years of lipoprotein apheresis for familial hypercholesterolemia in Malaysia: A creative approach by a cardiologist in a developing country.

G. Watts, J. Defesche, K. Khoo, 2016, Journal of clinical lipidology.

PCSK9 inhibition 2018: riding a new wave of coronary prevention.

G. Watts, N. Ward, M. M. Page, 2019, Clinical science.

Liver transplantation for the treatment of homozygous familial hypercholesterolaemia in an era of emerging lipid‐lowering therapies

P. Gow, R. O’Brien, E. Ekinci, 2014, Internal medicine journal.

PCSK9 inhibitors - mechanisms of action.

G. Watts, M. M. Page, 2016, Australian prescriber.

Risk of undetected cases of gestational diabetes mellitus during the COVID‐19 pandemic

J. Conradie, M. M. Page, E. Gianatti, 2020, The Medical journal of Australia.

Lipoprotein apheresis and PCSK9 inhibitors for severe familial hypercholesterolaemia: Experience from Australia and New Zealand

G. Watts, J. Burnett, C. Florkowski, 2020, Journal of clinical apheresis.

Recessive inheritance of diabetes: the syndrome of diabetes insipidus, diabetes mellitus, optic atrophy and deafness.

C. Edwards, A. C. Asmal, M. M. Page, 1976, The Quarterly journal of medicine.

Approach to the diagnosis of secondary hypertension in adults

J. Conradie, M. M. Page, M. Gillett, 2021, Australian prescriber.

Improved technical success and radiation safety of adrenal vein sampling using rapid, semi-quantitative point-of-care cortisol measurement

P. Glendenning, S. Vasikaran, D. Ramsay, 2018, Annals of clinical biochemistry.

Isolated brachydactyly type E and idiopathic pancreatitis in a patient presenting to a lipid disorders clinic

P. Glendenning, J. Burnett, A. Hooper, 2017, BMJ Case Reports.

In Memoriam: A cardiologist's unique cholesterol journey in Malaysia: Dato' Dr Kah-Lin Khoo, MD, FRCP, FACC, FESC, FCCP (December 18, 1938-November 7, 2014).

G. Watts, M. M. Page, 2016, Journal of clinical lipidology.

Integrated Guidance for Enhancing the Care of Familial Hypercholesterolaemia in Australia.

Andrew B. Kirke, A. Keech, H. White, 2020, Heart, lung & circulation.

Synopsis of an integrated guidance for enhancing the care of familial hypercholesterolaemia: an Australian perspective

Andrew B. Kirke, Clara K. Chow, A. Keech, 2021, American journal of preventive cardiology.

Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9.

G. Watts, A. Sniderman, C. Stefanutti, 2015, Clinical science.

Emerging PCSK9 inhibitors for treating dyslipidaemia: buttressing the gaps in coronary prevention

G. Watts, M. M. Page, 2015, Expert opinion on emerging drugs.

Earlier translation of evidence into public subsidy may prevent morbidity and mortality: an example using statins in diabetics with normal cholesterol levels

M. Hobbs, T. Briffa, F. Sanfilippo, 2012, Australian and New Zealand journal of public health.

The challenge of improving the diagnostic yield from metanephrine testing in suspected phaeochromocytoma and paraganglioma

P. Glendenning, S. Vasikaran, K. Hoad, 2018, Annals of clinical biochemistry.

Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?

J. Burnett, A. Hooper, M. M. Page, 2016, Expert opinion on pharmacotherapy.

Evolocumab in the treatment of dyslipidemia: pre-clinical and clinical pharmacology

G. Watts, M. M. Page, 2015, Expert opinion on drug metabolism & toxicology.

Pharmacokinetics of flucloxacillin during prolonged intermittent renal replacement therapy in a 76-year-old man

J. Roberts, M. Rawlins, B. D. De Keulenaer, 2019, Journal of chemotherapy.

Pharmacokinetics of Benzylpenicillin (Penicillin G) during Prolonged Intermittent Renal Replacement Therapy

E. Litton, J. Roberts, M. Rawlins, 2019, Chemotherapy.

The adrenal vein sampling outcomes study (AVOS): success rates following adrenalectomy for unilateral primary aldosteronism.

P. Glendenning, S. Vasikaran, Jun Yang, 2023, Pathology.

Psychotropic drugs and dentistry

M. M. Page, Luke M Somerville-Brown, 2007 .